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Frequently, primary care providers continue to manage the overall medical care of cancer patients. With newer and often more
potent antitumor agents, patients may present to their local physicians with drug-induced toxicities such as hypertension induced
by vascular endothelial growth factor (VEGF) inhibitors. It is imperative that these healthcare providers are aware of basic aspects
ofthisdrugclass,asitsusehasincreasedsigniﬁcantlyinthelastseveralyears.Uncontrolled ormalignanthypertension dueto these
agents shouldbe recognized readily and treated early to prevent more severe outcomes.This overview provides a brief background
on the role of VEGF and angiogenesis in tumor metabolism as well as theories of the mechanism of VEGF inhibitors and
hypertension. Helpful clinical practice aspects including the types of inhibitors used in the United States and their pharmacologic
characteristics will be discussed. Also, diagnosis and treatment of hypertension induced by vascular endothelialgrowth factors are
reviewed. A summary of key aspects of this drug class and hypertension is included.
1.Introduction
Cancer treatment continues to advance rapidly, and patients
may experience side eﬀects from newer treatments that
are unfamiliar to their physicians. The intricacies of many
diseases may necessitate severalclinicians managing multiple
diseases in an individual. The primary care physician often
continues to oversee care of a patient’s chronic illnesses such
ashypertension ordiabeteswhile the oncologistmanages the
patient’scancer treatment. With newer chemotherapy agents
now available that are not similar to traditional chemother-
apy agents such as VEGF inhibitors, non-oncology clinicians
may not readily recognize common side eﬀects induced by
these agents.
Common cancers, such as colorectal and breast cancers
are treated with these agents, VEGF inhibitors, and it is likely
as their use becomes more widespread that primary care
physicians will care for patients receiving such agents. There-
fore, it is imperative that primary care physicians become
more familiar with the VEGF inhibitors and their common
sideeﬀects.One ofthemost important sideeﬀectsassociated
with VEGF inhibitors is hypertension, and if left untreated,
it could have detrimental cardiovascular complications such
as renal damage or stroke. The objective of this review is
to outline aspects of VEGF inhibitors used in the United
States, including their proposed mechanism of action in
inducing hypertension, the rates and severity of associated
hypertension, and the current treatment recommendations
for hypertension secondary to these agents.
2.ScientiﬁcBackground of Angiogenesis
Angiogenesis is the complicated process of creating new
blood vessels. Aberrant angiogenesis plays a role in certain
diseases, including diabetes, psoriasis, rheumatoid arthritis,
and various malignancies [1, 2]. Neoangiogenesis is a
signiﬁcant factor in a tumor’s ability to grow and metastasize
[3].
During tumor growth, there are two commonly de-
scribed phases: a prevascular phase and a vascular phase.
During the prevasculature phase, the tumor grows by2 Cardiology Research and Practice
utilizing nutrients and oxygen obtained from the host’s
vasculature. In general, cell propagation and death are in
balance and tumor expansion is minimal and does not
exceed more than a few millimeters. Tumor neovasculature
diﬀers from normal blood vasculature by being irregular,
heterogeneous, and leaky, and by showing no cleardiﬀerence
between arterioles and venules. Endothelial cells tend to
be irregularly shaped with frequent overlap and an overall
disorganized appearance [4]. During the vascular phase (or
neoangiogenesis), there is brisk ampliﬁcation of size and
metastatic capability[5].Severalfactors, suchas,tumortype,
cytokines, and proangiogenic genes can stimulate the tumor
from a dormant to an invasive state, “angiogenic switch” [6].
3.AngiogenesisInhibitors
Angiogenesis inhibitors block tumor angiogenesis and target
vascular endothelial cells. Several factors favor the use of
these agents over the use of conventional chemotherapeutic
agents. Because endothelial tumor cells are growing and
moving rapidly, angiogenesis inhibitors may be a more
eﬀective treatment option than conventional chemothera-
peutic agents [7]. Endothelial cells tend to be more uniform
in composition and have greater stability as a target than
would a diverse array of malignant cells [8]. Angiogenesis
inhibitors can readily reach the endothelium of malignant
cells by systemic administration. Synergistic eﬀects can be
produced when some angiogenesis inhibitors are combined
with cytotoxic drugs and radiation therapy [9].
Angiogenesis can be inhibited by targeting diﬀerent
mechanisms. Agentsmaybeadministered tobindangiogenic
factors (e.g., VEGF), block angiogenic factor receptors (anti-
VEGF-receptor antibodies), interrupt intracellular signaling
pathways (tyrosine kinase inhibitors), and mimic endoge-
nous angiogenesis inhibitors (angiostatin-1,-2,endostatin,
thrombospondin-1).
4.VascularEndothelialGrowthFactor(VEGF)
VEGF is one of the primary regulators of angiogenesis
and can initiate a network of signaling processes pro-
moting endothelial cell growth, movement, and survival
following the activation of the VEGF-receptor pathway. At
present, angiogenesis inhibitors are typically combined with
chemotherapy. Bevacizumab was the ﬁrst antiangiogenic
agent approved in the United States for the treatment of
colorectal cancer in combination with chemotherapy. Since
then,otherantiangiogenicagentshavebeenapprovedtotreat
various malignancies (Table 1)[ 10–15].
5.Hypertensionand VascularEndothelial
GrowthFactor (VEGF) Inhibitors
Hypertension is a frequent adverse event of VEGF inhibitors
but its incidence and severity vary by treatment agent. The
overall occurrence of hypertension induced by bevacizumab,
sorafenib, sunitinib, nilotinib, pazopanib, and dasatinib
ranges from 9% to 67%. More severe hypertension (grades
3, 4) ranges from 3% to 18% among these agents (Table 1)
[10–15]. Patients with underlying hypertension appear to be
more at risk for severe hypertension during cancer treatment
than patients without a prior diagnosis of hypertension.
Several mechanisms may induce VEGF inhibitor-related
hypertension. Rarefaction, a decreased number of small
arteries and arterioles, can result from treatment with VEGF
kinase inhibitors and may contribute to the development
of hypertension. Rarefaction of arterioles and capillaries
has been noted in 6- to 8-week-old hypertensive rats with
rapid microvascular rarefaction occurring after 3 days of
being fed a high-salt diet [16, 17]. This ﬁnding suggests
that rarefaction occurs relatively early in the development of
hypertension. Microvascular rarefaction has alsobeenshown
in hypertensive adults. Steeghs et al. ﬁrst demonstrated
capillary rarefaction in patients treated with telatinib (BAY
57–9352), an oral inhibitor of VEGF receptors-2 and -3
(VEGFR-2, -3) [18].
A second mechanism that may contribute to hyperten-
sion isincreased arterial stiﬀness inproximalordistalvessels.
Veronese et al. [19]foundthatpatientstreatedwithsorafenib
for 3 to 6 weeks showed a signiﬁcant increase in arterial
stiﬀness, as indicated by the central aortic augmentation
index and aortic pulse wave velocity. Plasma renin, aldos-
terone, and catecholamine levels were not aﬀected in those
patients,demonstratingthatrenovascularmeansandvolume
expansion were not considered major contributors to their
development of hypertension [19].
A third proposed mechanism that may contribute
to hypertension is increased vascular resistance due to
decreased nitric oxide and prostacyclin production. A pre-
vious study demonstrated that VEGF plays a signiﬁcant
role in maintaining basal vascular tone by regulating nitric
oxide synthesis [20]. Wheeler-Jones et al. demonstrated that
anotherpathwaymaybeinvolvedinmediatingthevasoactive
eﬀects of VEGF via prostacyclin release. Preliminary results
suggested that inhibiting signaling through the VEGF path-
way could lead to decreased nitric oxide and prostacyclin
production, thus increasing vascular resistance and blood
pressure (BP) [20].
6.TypesofVEGF-KinaseInhibitors
The VEGF-kinase inhibitors utilized currently in clinical
practice in the United Statesincludebevacizumab, sorafenib,
sunitinib, nilotinib, pazopanib, and dasatinib. Common
features of these drugs/inhibitors are outlined in Table 1.
6.1. Bevacizumab. Bevacizumab was the ﬁrst anti-VEGF
monoclonal antibody approved for clinical practice and has
been most frequently used to treat metastatic colorectal
cancer. Bevacizumab is a recombinant, humanized, mon-
oclonal antibody that binds to VEGF and prevents its
association with endothelial receptors. Bevacizumab inhibits
angiogenesis by VEGF binding. By inhibiting microvascular
growth, bevacizumab is thought to slow the growth of all
tissues, including malignant tissue. The half-life elimination
of bevacizumab is 20 days, with a range of 11 to 50 days.Cardiology Research and Practice 3
Table 1: Current VEGF kinase inhibitors in use in the United States [10–15].
Name
(proprietary name)
Bevacizumab
(Avastin)
Sorafenib
(Nexavar)
Sunitinib
(Sutent)
Nilotinib
(Tasigna)
Pazopanib
(Votrient)
Dasatinib
(Sprycel)
Mechanism of
action
Anti-VEGF
monoclonal
antibody
Tyrosine kinase
inhibitor; VEGF
inhibitor
Tyrosine kinase
inhibitor; VEGF
inhibitor
Tyrosine kinase
inhibitor
Tyrosine kinase
inhibitor; VEGF
inhibitor
Tyrosine kinase
inhibitor
Hypertension
(%)any grade 23–67 9–17 15–30 1–10 40 1–10
Hypertension (%)
grade 3 or more 5–18 Grade 3: 3–4
grade 4: <1 4–10 Not reported Grade 3: 4 Not reported
FDA-labeled
indication
GBM
Metastatic breast
cancer
Metastatic
colorectal cancer
Non-small cell
lung cancer
Liver carcinoma
Renal cell
carcinoma
GI stromal tumor
Renal cell
carcinoma
CML Advanced renal cell
carcinoma CML
Abbreviations: VEGF, vascular endothelial growth factor; FDA, Food and Drug Administration; GBM, glioblastoma multiforme; CML, chronic myelogenous
leukemia;GI, gastrointestinal.
Bevacizumab is administered intravenously. BP monitoring
is recommended every 2 to 3 weeks during bevacizumab
therapy. Other cardiovascular adverse eﬀects include arte-
rial thromboembolism (6%–9%), congestive heart failure
with prior anthracycline therapy (2%–4%), hypertensive
encephalopathy, and myocardial infarction [10].
Bevacizumab may potentiate the cardiotoxic eﬀects of
anthracyclines. Heart failure is more common when beva-
cizumab is administered to patients with prior exposure
to anthracyclines and/or left chest wall irradiation than
to patients without these prior exposures. Proteinuria may
occur with or without hypertension (any grade, 4%–36%)
and should be monitored during treatment. Patients with a
history of hypertension may have increased risk of protein-
uria during treatment. Patients with a 2+ or greater urine
dipstick reading should have a 24-hour urine collection test.
Those patients with morethan 2grams ofproteinuria during
the 24-hour period should have bevacizumab treatment
withheld,andtreatmentshouldberesumedwhentheprotein
level is less than 2 grams during a 24-hour period. If the
patient develops nephrotic syndrome, bevacizumab should
be discontinued [10].
6.2. Sorafenib. Sorafenib is a multikinase inhibitor that stalls
tumor growth and angiogenesis by inhibiting intracellular
RAF kinases (CRAF, BRAF, and mutant BRAF) and cell sur-
face kinase receptors VEGFR-2, VEGFR-3, platelet-derived
growth factor receptor-beta (PDGFR-β), c-kit receptor, and
FMS-like tyrosine kinase-3 (FLT3). Sorafenib is metabolized
by the liver via the cytochrome P450 3A4 enzyme (CYP3A4)
and UGT1A9 (UDP-glucuronosyltransferase 1-9). The half-
life elimination is 25 to 48 hours with a time at which
plasma level peaks of approximately 3 hours. Sorafenib is
administered orally. Monitoring the patient’s BP weekly is
recommended during the ﬁrst 6 weeks of sorafenib therapy.
Other cardiovascular adverse eﬀects of sorafenib include
cardiac ischemia/infarction (≤3%) [11].
6.3. Sunitinib. Sunitinib exhibits antitumor and antian-
giogenic properties by inhibiting multiple receptor tyro-
sine kinases, including PDGFR-α and PDGFR-β;V E G F R -
1, VEGFR-2, and VEGFR-3; FLT3; colony-stimulating factor
type-1; glial cell line-derived neurotrophic factor receptor.
Sunitinib is metabolized by the liver, predominantly by
CYP3A4. The half-life elimination period is 40 to 60 hours
with time to peak in plasma of 6 to 12 hours. Sunitinib is
administered orally [12]. Cardiac parameters recommended
for monitoring include the left ventricular ejection frac-
tion, cardiac risk factors, and electrocardiographic data at
baseline and periodically thereafter, along with BP. Adverse
cardiovascular eﬀects include a decrease in left ventricu-
lar ejection fraction (11%–21% of patients), heart failure
(≤15%),peripheral edema(11%),venousthrombotic events
(2%–3%), and myocardial ischemia (1%). Patients with an
ejection fraction of less than 50% and greater than 20%
below baseline butwithout symptoms of heart failure should
havethesunitinib dosereducedorthetreatmentinterrupted.
Sunitinib should be discontinued in those patients who
develop symptoms of heart failure. Sunitinib should also be
discontinued in patients who develop severe hypertension,
though treatment may be restarted after the hypertension
is controlled. Patients are at increased risk of atypical
rapid ventricular tachycardia, or torsades de pointes, and
if they have any of the following: taking antiarrhythmic
medications, prolonged QT interval syndrome, preexisting
bradycardia, and underlying cardiac disease [12].
6.4. Nilotinib. Nilotinib is an inhibitor of the Bcr-Abl
kinase that binds and stabilizes the inactive conformation
of the kinase domain of the Abl protein, which inhibits
proliferation of leukemic cell lines in patients with the
Philadelphia chromosome (Ph) associated with chronic
myelogenous leukemia (CML). Nilotinib is metabolized by
the liver via CYP3A4 to inactive metabolites with a half-life4 Cardiology Research and Practice
elimination period of 15 to 17 hours. Nilotinib is admin-
istered orally. Nilotinib can prolong the QTc interval and
predispose patients to torsades de pointes and sudden death
[13]. Using nilotinib in patients with a QTc interval >480
milliseconds is contraindicated; in those patients, prompt
attention and correction of electrolyte abnormalities (such
as hypokalemia and hypomagnesemia) are warranted [13].
Medications that prolong the QTc interval, such as amio-
darone hydrochloride, disopyramide phosphate, dofetilide,
ibutilide fumarate, procainamide hydrochloride, quinidine,
sotalol hydrochloride, haloperidol, methadone hydrochlo-
ride, levoﬂoxacin, and clarithromycin should be avoided or
substituted when nilotinib is used [21]. Avoid concomitant
administration of CYP3A4 inhibitors such as ketoconazole,
voriconazole, itraconazole, clarithromycin, ritonavir, and
grapefruit products. Patients may resume nilotinib within 2
weeks at the previous dose if their QTc interval returns to
<450 milliseconds and is within 20 milliseconds of the base-
line.IftheirQTcintervalisbetween450and480milliseconds
after 2 weeks, the nilotinib dose should be reduced. An
electrocardiogram (ECG) should be repeated approximately
7 days after any dose adjustments. Other cardiovascular
complications of nilotinib are peripheral edema (>10%),
angina, chest pain, hypertension, and pericardial eﬀusion in
1%–10% of patients [13].
6.5.Pazopanib. Pazopanib is amultityrosine kinase inhibitor
of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α and -β,ﬁ b r o b -
last growth factor receptor-1 and -3, cytokine receptor (kit),
interleukin-2 receptor inducible T-cell kinase, leukocyte-
speciﬁc protein tyrosine kinase, and transmembrane glyco-
protein receptor kinase [14].
Pazopanib disrupts angiogenesis in vivo by inhibit-
ing VEGF-induced VEGFR-2 phosphorylation. Pazopanib
is administered orally and is primarily metabolized via
the CYP3A4 (major) and CYP1A2 and CYP2C8 (minor)
pathways. The half-life elimination period of pazopanib is
approximately 30 hours. Prolonged QT interval syndrome
and torsades de pointes have been reported with use of
pazopanib. A QTc interval >500 milliseconds has been
reported in 1% of patients with renal cell carcinoma [14].
Torsades de pointes has been reported in less than 1%
of patients treated with pazopanib [14]. Drugs that are
CYP3A4 inhibitors (such as ketoconazole, ritonavir, and
clarithromycin) may increase pazopanib concentrations,
which may increase the risk of arrhythmias. Patients on
such medication combinations or those on medications that
prolong the QTc interval should be monitored closely for
ECG changes, and the pazopanib dose should be modiﬁed
as needed. A baseline ECG and serum electrolyte analysis
are required for patients on pazopanib. Other cardiovascular
complications of pazopanib include chest pain (5% of
patients), myocardial infarction and ischemia (2%), tran-
sient ischemic attack (1%), and hypertension (overall: 40%;
grade 3: 4%) [14]. Pazopanib should be avoided in patients
with evidence of cardiovascular events. In clinical trials
of renal cell carcinoma, the incidence of proteinuria was
reported at 8% (grade 3: <1%, and grade 4: <1%). Baseline
Table 2: Common terminology criteria for adverse events v3.0
(CTCAE): hypertension adult.
Grade
1
Asymptomatic, transient (<24hrs) increase by
>20mmHg (diastolic) or to >150/100 if previously
WNL; intervention not indicated
2
Recurrent or persistent (>24hrs) or symptomatic
increase by >20mmHg (diastolic) or to >150/100 if
previously WNL; monotherapy may be indicated
3 Requiring more than one drug or more intensive
therapy than before
4 Life-threatening consequences (e.g., hypertensive crisis)
5D e a t h
Abbreviations: WNL, within normal limits.
Publication date: August 9, 2006. Available at: http://ctep.info.nih.gov/
protocolDevelopment/electronic applications/docs/ctcaev3.pdf.
and periodic urinalysis to detect the presence of protein
should be performed and if grade 4 proteinuria develops,
pazopanib should be discontinued [14].
6.6. Dasatinib. Dasatinib inhibits the following kinases:
BCR-Abl, Src family (Src, Lck, Fyn), c-kit,E p h A 2 ,a n d
PGDFR-β. On the basis of modeling studies, dasatinib is
predicted to bind the multiple conformations of the Abl
kinase [15]. Dasatinib is administered orally. Dasatinib is
extensively metabolized via CYP3A4 and has a 3- to 5-
hour elimination half-life period [15]. Some of dasatinib’s
major cardiovascular complications include ﬂuid retention
(21%–35% of patients; grades3 ,4 :4 % – 8 % )a n dp e r i c a r -
dial eﬀusion (<3 % ;g r a d e s3 ,4 :<3%). Heart failure and
cardiac dysfunction (cardiomyopathy, diastolic dysfunction,
decreased ejection fraction, ventricular dysfunction, chest
pain, ventricular arrhythmia, and hypertension) have been
reported in less than 4% of patients treated with dasatinib.
Dasatinib may prolong the QTc interval, with a reported
incidence of less than 1%. Patients with hypokalemia
or hypomagnesemia and those taking an antiarrhythmic
medication should be closely monitored while on dasatinib
therapy [15].
7.Diagnosis ofHypertension
In cancer trials, hypertension is commonly classiﬁed as
an adverse event according to the Common Terminology
Criteria for Adverse Events (CTCAE) of the National Can-
cer Institute and is based on the presence of symptoms,
high BP, and need for antihypertensive therapy (Table 2)
[22]. A commonly used treatment guideline is that of
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7) [23]. In this classiﬁcation system, BP
is categorized as normal, prehypertension, or hypertension
(Table3).Thus,CTCAEaidsinclassifyinghypertension asan
adverse event or caused by the VEGF inhibitor whereas JNC
7 is used to deﬁne and categorize hypertension throughoutCardiology Research and Practice 5
theadministration oftheVEGF inhibitor. Apatientreceiving
a VEGF inhibitor may have a normal BP reading when the
drug is initiated on the basis of JNC 7 criteria and then may
developprehypertension or stage 1 or 2 hypertension during
treatment. If the patient develops stage 1 or 2 hypertension
following a normal baseline BP, his/her hypertension will be
classiﬁedasgrade1orhigherontheCT CAEscale,depending
on the duration of the BP increase, the development of
symptoms, the degree of BP increase from the baseline
reading, or the need for multidrug antihypertensive therapy.
According to JNC 7, three objectives should be addressed
when evaluating patients with hypertension [23]. These
objectivesincludeidentifying possibleetiologiesofhyperten-
sion, assessing lifestyle (including identifying cardiovascular
risk factors or other comorbid conditions that may aﬀect
prognosis or treatment of hypertension), and evaluating the
presence or absence of hypertension-induced target organ
damage.
8.Timing andDurationof Hypertension
AssociatedwithVEGFinhibitors
The temporal relationship between the initiation of VEGF
inhibitors and the onset of hypertension should be carefully
examined. A report by Yang et al. [24] noted that the median
interval from the ﬁrst dose of high-dose bevacizumab to
the onset of hypertension was 131 days (range: 7–316
days). Johnson et al. reported that the largest increase in
systolic pressure was between 7 to 14mmHg on day 42
of bevacizumab treatment [25]. Seven of 12 patients with
major increases in their BP had pre-existing hypertension
[25].Aretrospective chart reviewof144patientstreatedwith
bevacizumab found that hypertension occurred in 35% of
patients after a median of 11 weeks [26]. The majority of
thesepatientsweresubsequentlytreatedwithanangiotensin-
convertingenzyme(ACE)inhibitorforhypertensioncontrol.
In a study by Zhu et al., the incidences of hypertension
in patients receiving low-dose (3.5 or 7.5mg/kg/dose) and
high-dose (10 or 15mg/kg/dose) bevacizumab ranged from
2.7% to 32.0% and from 17.6% to 36.0%, respectively
[27]. Thus, the incidence of hypertension appeared to be
dose-dependent, with increased incidence of hypertension
in those patients on high-dose bevacizumab. A retrospective
chart review to determine the adverse eﬀects of beva-
cizumab therapy found no signiﬁcant increased incidence
of hypertension in patients ≥75 years old [28]. In a small
retrospective study, African Americans were more likely
than non-African Americans to develop hypertension with
bevacizumab treatment [29]. Another potential risk for
bevacizumab-induced hypertension is high-dose treatment
in patients with underlying renal cell carcinoma; the patients
inthisstudyhadanoverallhypertensionincidencefrom26%
to 36% [24, 30]. In previous clinical trials, bevacizumab-
induced hypertension occurred with a BP increase at any
time during treatment.
In sunitinib-treated patients, increases in BP were shown
during the second treatment cycle [31]w h e r e a sw h e n
sorafenib was used there was frequently an increase in BP
Table 3:JointNationalCommission7(JNC7)BloodPressure(BP)
Classiﬁcation.
Normal BP
Systolic: <120mmHg;
Diastolic: <80mmHg
Prehypertension
Systolic: 120–139mmHg;
Diastolic: 80–89mmHg
Treatment required in
high-risk cardiovascular
patients
Stage 1 hypertension
Systolic: 140–159mmHg;
Diastolic: 90–99mmHg
Treatment required
Stage 2 hypertension
Systolic: >160mmHg;
Diastolic: >100mmHg
Treatment required
Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.
pdf.
(≥20% systolic and ≥10% diastolic) after 3 weeks of
treatment, with a BP plateau afterwards [32]. In a phase 2
open-label study ofpatients with Philadelphia chromosome-
positive CML in the chronic phase following imatinib
resistance and intolerance, Kantarjian et al. reported the
incidences of pleural eﬀusion and ﬂuid retention as 1% and
very rare (<1%), respectively, in association with nilotinib.
In the same study, prolongation of the QTc interval >500
milliseconds was observed in 0.7% of patients [33].
In a phase 2 study of cancer patients with metastatic or
recurrent invasive breast cancer treated with pazopanib, 52%
of patients had hypertension (any grade); the incidence of
grade 1 or2 hypertension was 38% and grade 3hypertension
was 14%. In this study, the authors concluded that develop-
ment ofhypertension might be a predictor ofresponse to the
angiogenesis inhibitor, as 9 (75%)ofthe 12 patientswho had
stable disease or a partial response developed hypertension
whereas only 3 (43%) of the 7 who had progressive disease
developed hypertension (P = .33). The time to progression
was longer in patients who developed hypertension than in
those who did not (5.3 months versus 1.7 months, resp.).
This study did not provide any statistical analysis for the
time to progression in the two groups (with and without
hypertension) during treatment with pazopanib. Therefore,
theroleofhypertensionintheresponsetopazopanibtherapy
needs to be validated [34].
In patients treated with dasatinib, the risk of pleural
eﬀusion, pericardial eﬀusion, and severe pulmonary edema
may be related to the dose they receive. In a study of 138
patients with CML, Quint´ as-Cardama et al. reported a 35%
overall incidence of pleural eﬀusion (grades 3, 4 in 17%
of patients). The researchers used multivariate analysis to
determine that a history of cardiac disease, hypertension,
and use of a twice-daily dosing schedule (versus once daily)
were risk factors associated with the development of pleural
eﬀusions. The authors suggested that the following could
be used to manage cardiovascular complications associated
with dasatinib therapy: treatment interruption, changing the
dosing interval to daily, management of hypertension, and
the judicious use of diuretics, pulse steroids, and in severe
cases, thoracentesis [35].6 Cardiology Research and Practice
9.InterventionandTreatmentofVEGF
Inhibitor-Induced Hypertension
At present, there are no evidence-based guidelines or expert
consensus on the treatment of VEGF inhibitor-induced
hypertension diﬀering from the JNC 7 guidelines. However,
allpatientsshould haveoptimalBP controlprior toinitiating
treatment with any of the VEGF inhibitors.
Recommendations for bevacizumab caution its use in
patientswithpreexistinghypertensionandadvise closemon-
itoring of BP (at least every 2 to 3 weeks during treatment)
in all patients. Permanent discontinuation of bevacizumab
is recommended in patients who develop hypertensive crisis
or encephalopathy. For patients who develop uncontrolled
hypertension, therapy should be discontinued, at least
temporarily. There is no recommendation to continue to
monitor BP after therapy is discontinued, although it may
take several weeks for the drug to be eliminated [10].
It is recommended that patients receiving sorafenib have
weekly BP readings taken during the ﬁrst 6 weeks of therapy,
with periodic monitoring thereafter. Caution should be
used when prescribing sorafenib for patients with poorly
controlled hypertension [11].
Patients treated with sunitinib should have their therapy
interrupted if their hypertension is uncontrolled or severe
until the hypertension can be controlled. The BP of those
patients on sunitinib should be monitored closely if they
have been diagnosed previously with hypertension or poorly
controlled hypertension [12]. Also, patients treated with
nilotinib, pazopanib, or dasatinib should be monitored
closely for hypertension [13–15]. Any home monitoring
devices should be validated with clinic devices so that accu-
rate readings are recorded; this process ensures conﬁdence
in basing treatment interventions on readings taken at either
location (at home or in the clinic). All patients receiving
VEGF inhibitors should be encouraged to monitor their BP
at home. The frequency of the monitoring should dependon
whether the patient has preexisting hypertension, the level
of BP control prior to initiation, the dosage and type of
VEGF inhibitor, and other comorbidities, especially those
that increase cardiovascular risks.
Although there is no speciﬁc antihypertensive agent
recommended for VEGF inhibitor-induced hypertension,
both calciumchannel blockersand ACE inhibitors havebeen
used to successfully treat this hypertension. ACE inhibitors
have been proposed as a more eﬀective treatment because
angiogenesis-induced hypertension mediated through the
nitric oxide pathway may be aﬀected by ACE inhibitors
but not necessarily by calcium channel blockers [36]. ACE
inhibitors may also prevent proteinuria and plasminogen
activator inhibitor-1 expression [37]; however, treatment
suggestions for VEGF inhibitor-induced hypertension typi-
callyfollow theJNC7 guidelines,aspreviously outlined[23].
VEGF inhibitor-induced hypertension typically requires
treatment with more than one antihypertensive agent.
Careful BP monitoring with necessary adjustments in anti-
hypertensive medications are essential. Because sorafenib is
metabolized through the cytochrome p450 chain, nondihy-
dropyridine calciumchannel blockers(verapamilhydrochlo-
ride, diltiazem hydrochloride) should not be prescribed
in combination with sorafenib; both drugs inhibit the
CYP3A4 isoenzyme and may signiﬁcantly increase sorafenib
levels [11]. If calcium channel blockers are necessary for
BP control, the preferred choice is amlodipine besylate or
nifedipine. In those patients who have an increased risk
of developing heart failure and hypertension, medications
utilized for the management of heart failure are preferred
andarealsoeﬀectiveantihypertensivemedications(e.g.,ACE
inhibitors,betablockers,angiotensinreceptorblockers)[23].
A recent prospective clinical trial with cediranib, a
selective VEGF signaling inhibitor used in Europe, focused
on minimizing dose interruptions and reductions so that the
maximum dose intensity of cediranib could be utilized [38].
In this trial, 126 patients with advanced solid tumors were
randomized to 1 of 4 groups. The groups included cediranib
30 or 45mg/d with or without antihypertensive prophylaxis.
All patients who developed hypertension while on cediranib
therapy were treated with a standardized, predeﬁned hyper-
tension management algorithm that utilized a low dose of a
calcium channel blocker 3 to 7 days prior to initiating cedi-
ranib. They reported thatoverall cediranib was well tolerated
and that all groups achieved a high-dose intensity during
the ﬁrst 12 weeks of treatment; antihypertensive prophylaxis
did not result in reduced dose reductions or interruptions.
Increases in BP were noted early in treatment for all
groups and were managed successfully; severe hypertension
occurred in only 1 patient receiving prophylaxis versus 18
in the nonprophylaxis groups. The researchers concluded
that all four regimens were well tolerated with high-dose
cediranib but that no strategy was clearly superior [38]. In
previous cediranib studies, there was no preexisting anti-
hypertensive protocol management [39, 40]. The researchers
felt that early diagnosis and treatment of hypertension are
likely to decrease the severity of hypertensive events[39, 40].
Unfortunately there is no published data documenting the
time course of VEGF inhibitor-induced hypertension upon
withdrawal of the agent. Anecdotally, most patients seem to
have improvement of their blood pressure over several weeks
to months upon withdrawal of the agent.
10.FutureAspects
Maitland et al. proposed that increases in BP after treatment
with agents targeting VEGF signaling may be an eﬀective
biomarker of VEGF signaling inhibition and that dose titra-
tioncausing an increase in BPmay producebetterantitumor
eﬀectsand subsequentlyimprove clinical outcomesin cancer
patients as intended [39]. Future prospective studies are
needed to validate these preliminary observations. However,
there has been discussion that discontinuing these agents
because ofBP increases may hinder overall cancertreatment.
11.Summary
As cancer screening methods and detection rates for com-
mon cancers such as breast and colorectal cancer continue
to improve, many primary care physicians will likely care
for cancer patients being treated with VEGF inhibitors.Cardiology Research and Practice 7
These physicians and other healthcare providers will be
asked to help manage their patients’ hypertension and
other comorbidities. It is imperative that these clinicians be
familiar with the fact that hypertension can be induced by
VEGF inhibitors. The currently recommended management
ofVEGF-inducedhypertension issimilartothemanagement
of hypertension outlined in the JNC 7 guidelines. However,
baseline BP measurement should be performed prior to
administering any VEGF inhibitor, and elevated BP should
be treated if it is not in the normotensive ranges recom-
mendedbytheJNC7criteria.Allpatientsshouldhavecareful
BP monitoring during treatment, and aggressive BP treat-
ment should be instituted when increases in BP are noted.
Monitoring should be continued after treatment completion
in those patients who have increased BP during treatment
until the BP normalizes [41]. Treatment selections include
ACE inhibitors and calcium channel blockers, but that
decision should be made on the basis of individual patients’
characteristics, the type of VEGF agent used, and other
coexisting comorbidities. Those patients with undiagnosed
hypertension at baseline should be diagnosed and treated
appropriately before VEGF-inhibitor therapy is initiated.
As research continues to seek newer, more eﬀective
classes of pharmaceuticals to treat cancer, other harmful side
eﬀects like hypertension may be discovered. Careful report-
ing of adverse events is needed so that treatment-associated
events can be recognized and promptly addressed with
appropriate interventions so that oncologic interventions
can be administered safely.
12.KeyAspects
(i) VEGF inhibitors utilized in oncologic care in the
United States include bevacizumab (Avastin),
sorafenib (Nexavar), sunitinib (Sutent), nilotinib
(Tasigna), pazopanib (Votrient), and dasatinib
(Sprycel).
(ii) VEGF inhibitors frequently increase BP readings
during treatment.
(iii) Patients with hypertension and other cardiac comor-
biditiesshouldbecarefullyassessed priortoinitiating
treatment with VEGF inhibitors.
(iv) Baseline BP readings should be taken prior to VEGF
inhibitor treatment, and those patients with pre-
hypertension and undiagnosed hypertension should
be started on appropriate anti-hypertensive manage-
ment.
(v) Patients with uncontrolled hypertension prior to
initiating treatment with VEGF inhibitors should
undergo appropriate evaluation and treatment so
that BP control is achieved.
(vi) At this time, the JNC 7 guidelines for diagnosis
and management ofhypertension are appropriate for
VEGF-induced hypertension.
(vii) ACE inhibitors and calcium channel blockers have
been utilized to manage VEGF-induced hyperten-
sion. However, no signiﬁcant evidence exists to sup-
port these selections, and, therefore, hypertension
treatment selections should be made on the basis of
JNC 7 recommendations.
(viii) Multiple antihypertensives may be necessary for
some patients with VEGF-induced hypertension.
(ix) Posttreatment (no longer being treated with a VEGF
agent) monitoring may be necessary for those
patients who develop hypertension while on treat-
ment.
(x) Treatment should be discontinued in patients who
develop malignant hypertension.
(xi) Treatment should be discontinued in patients who
develop severe hypertension until appropriate hyper-
tension management is attained.
(xii) Some VEGF inhibitors can prolong the QTc interval.
Periodic ECG monitoring is required in patientswith
a history of, or who are at risk of, prolonged QT
interval syndrome (those patients with electrolyte
abnormalities or those patients on multiple medica-
tions that can induce or inhibit VEGF inhibitors).
(xiii) Because some VEGF inhibitors can cause ﬂuid
retention in patients, assessment of cardiopulmonary
function is required.
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